In line with the aforementioned data linking D1R activation by SGAs (clozapine and aripiprazole) and the induction of pro-cognitive effects, also in the case of asenapine, its ameliorative effect on PCP-induced memory impairment can be blocked through the administration of a selective a D1R antagonist [102]. The gene discussed is DRD1; the disease is memory impairment.